Evotec SE

EVO

Healthcare|Drug Manufacturers - Specialty & Generic|DE

$1.69

-0.09 (-4.79%)

Tangible Book / Share

$1.80

Cash / Share

$1.18

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07595458 Phase 1 Study on the Safety, Tolerability, and Pharmacokinetics of JST-018 in Healthy Adults	Antiviral Drug	P1	Recruiting	48	RCT, Double-blind	JST-018 combination of 3 monoclonal antibodies, Placebo
NCT06943378 Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults	Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults	P1	Active	104	RCT, Double-blind	Monoclonal antibody JST-010, Placebo
NCT04084145 National Unified Renal Translation Research Enterprise - Chronic Kidney Disease	Chronic Kidney Diseases		Active	3,004	—	—
NCT00738595 Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.	Smoking Cessation	P2	Completed	400	RCT, Double-blind	EVT 302, Placebo, EVT 302 plus open label Nicotine replacement, Placebo plus open label Nicotine Replacement
NCT00401284 Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness	Sleep Initiation and Maintenance Disorders	P2	Completed	135	RCT, Double-blind	EVT 201
NCT00622752 Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes	Smoking Cessation	P2	Completed	90	RCT, Double-blind	EVT 302, 10 mg, placebo, Nicotine replacement therapy (NRT)
NCT00380003 Efficacy Study of EVT 201 to Treat Insomnia	Sleep Initiation and Maintenance Disorders	P2	Completed	66	RCT, Double-blind	EVT 201
NCT00526968 The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function	Human Volunteers	P1	Completed	19	RCT, Double-blind	EVT 101, EVT 101, placebo
NCT05154409 Blood and Urine Sample Collection From Healthy Volunteers	Healthy		Completed	100	—	—